Dipti Patel-Donnelly

Assistant Professor

19992019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Dipti Patel-Donnelly is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles
Waldenstrom Macroglobulinemia Medicine & Life Sciences
Multiple Myeloma Medicine & Life Sciences
Mantle-Cell Lymphoma Medicine & Life Sciences
Video Microscopy Medicine & Life Sciences
Marginal Zone B-Cell Lymphoma Medicine & Life Sciences
Dacarbazine Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1999 2019

Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study

Awan, F. T., Thirman, M. J., Patel-Donnelly, D., Assouline, S., Rao, A. V., Ye, W., Hill, B. & Sharman, J. P., Jan 1 2019, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalArticle

B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Confidence Intervals
Disease-Free Survival
Fatigue

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma

Burke, J. M., Shustov, A., Essell, J., Patel-Donnelly, D., Yang, J., Chen, R., Ye, W., Shi, W., Assouline, S. & Sharman, J., Jan 1 2018, (Accepted/In press) In : Clinical Lymphoma, Myeloma and Leukemia.

Research output: Contribution to journalArticle

Lymphoma, Large B-Cell, Diffuse
Syk Kinase
6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine
Disease-Free Survival
Confidence Intervals

An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma

Andorsky, D. J., Kolibaba, K. S., Assouline, S., Forero-Torres, A., Jones, V., Klein, L. M., Patel-Donnelly, D., Smith, M., Ye, W., Shi, W., Yasenchak, C. A. & Sharman, J. P., Jan 1 2018, (Accepted/In press) In : British Journal of Haematology.

Research output: Contribution to journalArticle

Mantle-Cell Lymphoma
Waldenstrom Macroglobulinemia
Non-Hodgkin's Lymphoma
Follicular Lymphoma
Confidence Intervals

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

Friedberg, J. W., Forero-Torres, A., Bordoni, R. E., Cline, V. J. M., Patel-Donnelly, D., Flynn, P. J., Olsen, G., Chen, R., Fong, A., Wang, Y. & Yasenchak, C. A., Dec 28 2017, In : Blood. 130, 26, p. 2829-2837 9 p.

Research output: Contribution to journalArticle

Dacarbazine
Hodgkin Disease
Survival
Toxicity
Comorbidity

WALDENSTRÖM'S MACROGLOBULINEMIA MASQUERADING AS BIRDSHOT CHORIORETINOPATHY

Kim, J. S., Jaworski, L., Patel-Donnelly, D., Nussenblatt, R. B. & Nida Sen, H., Jan 1 2017, In : Retinal Cases and Brief Reports. 11, 2, p. 152-155 4 p.

Research output: Contribution to journalArticle

Waldenstrom Macroglobulinemia
N,N-dimethyl-3,3-diphenyl-1-methylallylamine
HLA Antigens
Electroretinography
Vertebrate Photoreceptor Cells